HomeFilePharmacology

Pharmacology

View Category

Other

AHA 2018 | PIONEER-HF: Sacubitril/Valsartan in Acute Decompensated Heart Failure

Treating acute decompensated heart failure patients with an angiotensin receptor inhibitor plus a neprilysin receptor inhibitor significantly...
solaci -
Learn More
Other

AHA 2018 | New Dyslipidemia Guidelines Support Non-Statin Therapy and Coronary Artery Calcium Screening

While the guidelines do not recommend a specific treatment target, they suggest additional therapy in high-risk patients...
solaci -
Learn More
Other

AHA 2018 | No Benefits with Methothrexate as Anti-Inflammatory Drug

Low-dose methotrexate (a nonspecific anti-inflammatory agent used for the treatment of rheumatoid arthritis and other autoimmune disorders)...
solaci -
Learn More
Other

AHA 2018 | Canakinumab Reduces Hospitalization for Cardiac Failure in Respondents

The benefit was dose-dependent reduction, regardless the presence of absence of baseline cardiac failure. Patients with prior...
solaci -
Learn More
Antithrombotic Anticoagulants

Safety of Combining New Anticoagulant Agents and Dual Antiplatelet Therapy

Atrial fibrillation is the most common arrhythmia and its combination with a history of acute myocardial infarction...
solaci -
Learn More
Antithrombotic Anticoagulants

New Anticoagulant Agents in Atrial Fibrillation in Latin American Patients, Specifically

There is limited information on the use of antithrombotic therapies and their outcomes in Latin American patients...
solaci -
Learn More
Antithrombotic Anticoagulants

Galileo: Rivaroxaban After TAVR Stopped Due to Early Event Rates

Patients undergoing transcatheter aortic valve replacement (TAVR) randomized to rivaroxaban in the GALILEO trial experienced higher risk...
solaci -
Learn More
Pharmacology

Is Stage 1 Hypertension as Defined in ACC/AHA Guidelines Associated with Any Events?

New information has been published fast, and what we thought we knew about hypertension has also changed...
solaci -
Learn More